Proteome screening for tuberculosis outcome markers

Information

  • Research Project
  • 7084855
  • ApplicationId
    7084855
  • Core Project Number
    R21AI069135
  • Full Project Number
    1R21AI069135-01
  • Serial Number
    69135
  • FOA Number
    PA-03-80
  • Sub Project Id
  • Project Start Date
    5/1/2006 - 18 years ago
  • Project End Date
    12/18/2006 - 17 years ago
  • Program Officer Name
    LACOURCIERE, KAREN A.
  • Budget Start Date
    5/1/2006 - 18 years ago
  • Budget End Date
    12/18/2006 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/19/2006 - 18 years ago

Proteome screening for tuberculosis outcome markers

[unreadable] DESCRIPTION (provided by applicant): Our long-term goal is to test the hypothesis that profiles of antigen-specific immune responses vary over the course of infection with Mycobacterium tuberculosis, presumably in relation to changes of bacterial antigen composition occurring in response to host immune status. Changes in serum antibody profiles relative to outcome of M. tuberculosis will be measured in a non-human primate model with state-of-the-art, high-throughput screening of a ~500-protein M. tuberculosis microarray chip using sera already collected serially from cynomolgus macaques exhibiting either active disease or latent infection with/without subsequent reactivation. Target antigens identified in the antibody screen will be further purified and used for monitoring antigen-specific T cell responses over the course of ongoing experimental infection. Identification of outcome-specific immune profiles in primates is expected to help identify human immune markers of progression from latent infection to active tuberculosis that are detectable before clinical or bacteriological indicators of active disease. Identification of markers of infection outcome in macaques would also enhance the value of non-human primate models of tuberculosis for vaccine and drug evaluation. [unreadable] [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R21
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100263
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:100263\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PUBLIC HEALTH RESEARCH INSTITUTE
  • Organization Department
  • Organization DUNS
  • Organization City
    NEWARK
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    071033535
  • Organization District
    UNITED STATES